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Mechanisms by which the plus-sense RNA genomes of picornaviruses are replicated remain poorly defined,
but existing models do not suggest a role for sequences encoding the capsid proteins. However, candidate RNA
replicons (DP1bgal and DP1Luc), representing the sequence of human rhinovirus 14 virus (HRV-14) with
reporter protein sequences (b-galactosidase or luciferase, respectively) replacing most of the P1 capsid-coding
region, failed to replicate in transfected H1-HeLa cells despite efficient primary cleavage of the polyprotein. To
determine which P1 sequences might be required for RNA replication, HRV-14 mutants in which segments of
the P1 region were removed in frame from the genome were constructed. Mutants with deletions involving the
5*-proximal 1,489 nucleotides of the P1 region replicated efficiently, while those with deletions involving the 3*
1,079 nucleotides did not. Reintroduction of the 3* P1 sequence into the nonreplicating DP1Luc construct
resulted in a new candidate replicon, DP1Luc/VP3, which replicated well and expressed luciferase efficiently.
Capsid proteins provided in trans by helper virus failed to rescue the nonreplicating DP1Luc genome but were
able to package the larger-than-genome-length DP1Luc/VP3 replicon. Thus, a 3*-distal P1 capsid-coding se-
quence has a previously unrecognized cis-active function related to replication of HRV-14 RNA.
The picornaviruses comprise a large and diverse group of
positive-strand RNA viruses which have a common genetic
organization and replication strategy and which are pathogenic
in a variety of animal species. In each of these viruses, the
dominant feature of the organization of the genome is the
presence of a single large open reading frame (ORF), which
encodes a multifunctional viral polyprotein. The viral capsid
proteins are encoded by a segment of RNA (P1 segment)
located at or near the 59 end of the ORF, upstream of the P2
and P3 segments, which encodes a variety of nonstructural
proteins involved in replication of the virus (46). In two closely
related picornavirus genera which are important causes of dis-
ease in humans, enteroviruses (which include the polioviruses)
and rhinoviruses, the P1 segment is located at the extreme 59
end of the ORF, and primary cleavage of the viral polyprotein
occurs at the carboxyl terminus of the expressed P1 protein.
This structural protein intermediate is subsequently further
proteolytically processed into several capsid precursor pro-
teins: VP0 (representing VP4 plus VP2), VP3, and VP1 (see
Fig. 1). While nontranslated RNA sequences located upstream
and downstream of the ORF contain cis-active elements which
are critical for replication, and while translation of the P2/P3
coding region appears to be cis active with respect to viral
replication (50), the available evidence suggests that the P1
capsid-coding sequence is not required for viral RNA ampli-
fication.
The absence of a role for P1 sequences in the replication of
poliovirus is supported by the natural occurrence of defective
interfering particles with large deletions in this region of the
genome (11, 12, 26). In addition, several studies demonstrate
that artificially constructed poliovirus genomes with deletions
in the P1 region retain all the genetic information necessary for
RNA replication (13, 20, 24). Other, more recent studies indi-
cate that poliovirus P1 sequences can be replaced by RNA
encoding heterologous proteins without compromising viral
RNA replication (3, 9, 36). Such subgenomic P1-deleted po-
liovirus genomes have been referred to as replicons or mini-
replicons, and those expressing heterologous proteins may be
valuable for the study of various aspects of virus multiplication
or as general-purpose gene expression vectors (3, 9, 36, 40).
Among the poliovirus replicons which have been described,
there are several examples of replicating RNAs which contain
very large deletions in the P1 region. Some of these deletions
are much larger than those present in naturally occurring de-
fective interfering poliovirus particles (23, 26, 41), which usu-
ally retain VP4 and VP1 coding sequences near the 59 and 39
limits of the P1 segment (10, 20, 26). Despite this, these arti-
ficial replicons still retain efficient RNA replication functions
(3, 13, 24, 41).
The successful development of poliovirus replicons express-
ing heterologous proteins led us to consider the possibility that
encapsidated rhinovirus replicons have unique potential for
the delivery and expression of foreign genes in human airway
cells. The rhinoviruses include approximately 100 serologically
distinct pathogens which primarily infect human epithelial air-
way cells and which are important causative agents of the
common cold (15, 19). The RNA genomes and nonstructural
proteins of these viruses share striking similarities with those of
poliovirus, as does the structure of the virus capsid (8, 35, 45).
However, among several rhinovirus serotypes, some important
differences do exist, including the shorter length of the rhino-
virus 59 nontranslated RNA (59NTR) (38), sequence require-
ments for substrate recognition by the rhinovirus proteases (8,
49), and utilization of specific cellular receptors (14, 22).
To our knowledge, there are no prior reports describing the
construction of rhinovirus replicons or even descriptions of
naturally occurring P1-deleted defective interfering human rhi-
novirus (HRV) genomes. However, several infectious HRV
cDNA clones have been constructed and are available for such
studies (17, 28, 32). Here, we describe the successful construc-
tion of a subgenomic HRV-14 replicon, DP1Luc/VP3, which
expresses high levels of a foreign reporter protein, firefly lu-
* Corresponding author. Phone: (919) 966-2536. Fax: (919) 966-
6714.
1941
ciferase, in cultured cells. The design of this construct involved
the direct fusion of the luciferase coding sequence to the in-
ternal ribosomal entry site present in the 59NTR of HRV-14,
resulting in the removal of 1.5 kb of P1 sequence. However,
during the course of these experiments, we found that repli-
cation of HRV-14 RNA was dependent on the retention of
sequence near the 39 end of the P1 segment (VP3-VP1 coding
region). This finding demonstrates an important, previously
unrecognized difference in the replication strategies of entero-
viruses and rhinoviruses and suggests a novel role for P1 RNA
sequences in the replication of rhinoviruses.
MATERIALS AND METHODS
Cells. H1-HeLa cells were obtained from the American Type Culture Collec-
tion and maintained in 13 minimal essential medium (MEM) supplemented
with Earle’s salts (Gibco/BRL, Life Technologies Inc., Grand Island, N.Y.),
L-glutamine, and 10% fetal calf serum.
Virus. HRV-14 was recovered following transfection of H1-HeLa cells with
RNA transcribed from the infectious cDNA clone, pWR3.26, a generous gift
from Roland Rueckert, University of Wisconsin at Madison (28). For prepara-
tion of virus stocks, monolayers of H1-HeLa cells in a 100-mm-diameter dish
were infected with approximately 107 PFU of virus. After removal of the inocula,
5 ml of complete medium was added and the monolayer was incubated at 348C
for 24 h, at which time virus was harvested from cytoplasmic extracts as previ-
ously described (28, 48). The titer of the resulting virus stock was .108 PFU/ml.
For plaque assay of HRV-14, H1-HeLa cell monolayers in 60-mm dishes were
inoculated with 200 ml of virus diluted in 13 phosphate-buffered saline (PBS)
with 0.1% bovine serum albumin and overlaid 30 min later with MEM containing
5% fetal calf serum 13 tryptose-phosphate (Gibco/BRL), and 0.9% agarose.
After incubation at 348C for 48 to 72 h, the cell monolayers were stained with
crystal violet or neutral red.
Antibodies. A polyclonal rabbit antiserum to HRV-14 was a kind gift from
Anne Mosser, University of Wisconsin at Madison. In a microtiter neutralization
assay, a 1:500 dilution of this antiserum protected 5 3 104 HeLa cells against
infection with 5 3 104 PFU of HRV-14. Polyclonal rabbit antibodies to b-ga-
lactosidase (5Prime-3Prime, Inc., Boulder, Colo.) and luciferase (East Acres
Biologicals, Southbridge, Mass.) were obtained from commercial sources.
Construction of HRV-14 replicons and P1 segment deletion mutants. Candi-
date replicons were constructed from the HRV-14 infectious cDNA, pWR3.26
(28), as follows. Nucleotide positions are based on the HRV-14 sequence pro-
vided by Lee et al. (28). To facilitate replicon construction, a shuttle vector
(pSPHRV5) was prepared by excising the small SalI-StuI fragment (which con-
tains nucleotides [nt] 1 to 851 of HRV-14) from pWR3.26 and inserting this
fragment into the SalI and PvuII sites in pSP64 (Promega Corp., Madison, Wis.).
The bacterial b-galactosidase and firefly luciferase coding sequences were am-
plified by PCR from the plasmids pSVbgal and pGem-luc (Promega), respec-
tively, with PCR primers with sequences containing restriction endonuclease
sites permitting in-frame fusions with the HRV-14 genome. The PCR primers for
b-galactosidase were 59-GCTCTAGAtgatcatgGTCGTTTTACACGTCG-39 and
59-CCGCCCGGGcctaggtcctaaaccataggatttaatgtcacctttTTGACACCAGACC
AA-39 (where the lowercase bases represent HRV-14 sequences and the italic
bases represent unique restriction sites), while the PCR primers for amplification
of the luciferase sequence were 59-GCCCGATCCAAtgatcatgGAAGACGCC-39
and 59-CAGTTACATTTTAcctaggtcctaaaccataggatttaatgtcacctttCAATTTGGA
CTTTCCG-39. PCR-amplified products containing b-galactosidase sequences
were digested with XbaI and SmaI and cloned into unique sites in the vector
pSP64 to create the shuttle vector pSPb-gal. The complete b-galactosidase cod-
ing sequence was excised from this plasmid by digestion with BclI (partial) and
SmaI and cloned into unique sites of pSPHRV5, creating pSPHRVb-gal which
contains the b-galactosidase coding sequence fused to the HRV-14 internal
ribosome entry site. PCR-amplified products containing luciferase were digested
with BclI and AvrII and similarly cloned into the unique sites pSPHRVb-gal,
replacing the b-galactosidase coding sequence with the luciferase sequences and
creating the plasmid pSPHRVLuc. Large segments within the PCR-amplified
reporter gene sequences were subsequently replaced with plasmid DNA (non-
PCR amplified) sequences by using unique sites near the ends of each amplified
sequence (ClaI to NdeI for b-galactosidase, and XbaI to ClaI for luciferase). Any
remaining PCR-amplified sequences were confirmed by direct sequencing of
plasmid DNA. Final construction of full-length candidate replicons was accom-
plished by removing the small SalI-AvrII fragments from each of the resulting
shuttle plasmids. The SalI-AvrII b-galactosidase fragment was inserted at unique
SalI and AvrII sites within pWR3.26 to create pDP1bgal. The SalI-AvrII lucif-
erase fragment was inserted into pDP1bgal, replacing the 59NTR–b-galactosi-
dase sequence with 59NTR-luciferase sequences to create pDP1Luc. In both of
the final constructs, the amino terminus of the reporter sequence was fused in
frame to the authentic HRV-14 initiator codon while the carboxyl terminus of
the reporter sequence was fused in frame to the carboxyl terminal 7 amino acid
residues of VP1, 30 nt upstream of the unique AvrII site at nt 3206 of the 2Apro
coding sequence (see Fig. 1).
Variants of these candidate replicons containing a lethal mutation in the 3Dpol
coding sequence were constructed by linearizing the pWR3.26 plasmid with SphI,
removing the resulting 39 protruding ends with T4 DNA polymerase (Boehring-
er-Mannheim Biochemicals, Indianapolis, Ind.), and religating the blunt-ended
molecules. This created plasmid pWR3.26(pol2), which contains a frameshift in
the HRV-14 polyprotein such that a stop codon terminates translation 26 amino
acids upstream of the conserved YGDD motif in 3Dpol. The small SalI-AvrII
fragments containing the reporter gene sequences described above were cloned
into pWR3.26(pol2) to create DP1bgal(pol2) and DP1Luc(pol2).
A third candidate replicon, pDP1Luc/VP3, which contains sequences coding
for part of VP3 and all of VP1, was constructed from pDP1Luc as follows. A PCR
product representing the 39 end of the luciferase coding sequence was amplified
with the primers 59-GGATACCGGGAAAACGCTGGG-39 and 59-CCCACCG
TACCTAGGccatggACCTTGAAACAAAGCTCCTCCTCCCAATTTGGACTT
TCCG-39. In this case, the downstream PCR primer resulted in a fusion of the
luciferase coding sequence with a downstream synthetic 3CDpro cleavage site,
followed by an NcoI site allowing an in-frame fusion within the VP3 sequence of
HRV-14. The PCR product was digested with PpuMI (a site 471 nt upstream of
the 39 end of the luciferase coding region) and AvrII and inserted into pSPHRV-
Luc to create pSPHRVLuc/VP3. Next, the SalI-NcoI fragment was excised from
this plasmid and cloned into unique sites in pSPcap (see below). Finally, the
small ClaI-AvrII fragment of the resulting clone was inserted into the pDP1Luc
replicon to create pDP1Luc/VP3 (see Fig. 7A).
The construction of in-frame deletions within the capsid-coding P1 sequence
of pWR3.26 was facilitated by subcloning the entire P1 region (SalI-AvrII frag-
ment) in the vector pSP64 to create pSPcap. This plasmid was digested by several
different enzymes to create a series of deletion mutants (see Fig. 4A). When
necessary, 39 ends were filled in by treatment with Klenow enzyme, prior to gel
purification and religation. The modified capsid sequences were excised from the
pSPcap derivatives by digestion with SalI and AvrII and reinserted into the
pWR3.26 vector. To retain the authentic AUG start codon in the pCapd4
construct, the linker 59-GATCATGAAGAACCAGTTAAAGATC-39 was in-
serted between the BclI and BglII sites. The initiator AUG codon (boldface type)
flanks the first nucleotide of the Thr-54 codon at nt 788 of the HRV-14 genome.
Plasmid DNAmanipulations were done by standard procedures (47). DNA for
use in ligations was purified by the GeneClean II procedure (Bio101, Inc., Vista,
Calif.). Each construct was sequenced across regions where replacements took
place to confirm the validity of the construction. The deletion constructs were
sequenced in the region of the deletion to confirm preservation of the reading
frame. DNA sequencing was done by the USB DTaq cycle sequencing system
(United States Biochemical Corp., Cleveland, Ohio).
In vitro transcription. For the production of virus from infectious transcripts,
pWR3.26 plasmid DNA was linearized with MluI, which cleaves immediately 39
of the poly(A) tail of the virus genome (28). For the replicon constructs, DNA
templates were linearized with SmaI, as the b-galactosidase gene contains nu-
merous MluI sites. For experiments comparing replication potential of tran-
scripts, other templates were also linearized with SmaI to maintain consistency.
SmaI cleaves the DNA templates 9 nt downstream of the poly(A) sequence. The
infectivity of RNA transcripts derived from pWR3.26 linearized with SmaI was
approximately twofold lower than that of transcripts derived from MluI-linear-
ized templates (31). RNA transcripts were synthesized at 378C for 1 h in 100-ml
reaction mixtures containing 1 to 2 mg of linearized template DNA, 40 mM
Tris-HCl (pH 7.6), 6 mM MgCl2, 5 mM dithiothreitol, 2 mM spermidine-HCl,
100 mg of nuclease-free bovine serum albumin per ml, 1.5 mM each nucleoside
triphosphate, 5 ml of RNasin (Promega), and 200 to 500 U of T7 RNA poly-
merase (Promega or New England Biolabs Inc., Beverly, Mass.). To remove
template DNA prior to transfection, 5 U of RQ1-DNase (Promega) was added
to each reaction mixture and the mixtures were incubated at 378C for an addi-
tional 30 min. RNA products were quantified by determining the amount of
[a-32P]CTP incorporated into acid-insoluble precipitates. Alternatively, the
RNA content was determined by spectrophotometric analysis. Aliquots of tran-
scription reaction products were examined by sodium dodecyl sulfate (SDS)-
agarose gel electrophoresis in comparison with RNA standards to confirm tran-
script integrity. These reaction conditions consistently produced 1 to 3 mg of
RNA per ml.
RNA transfections. H1-HeLa cells were transfected by electroporation as
described by Liljestrom et al. (29). Optimal transfection of infectious RNA
transcripts was obtained at a setting of 980 V and 25 mF with a gene pulser
(Bio-Rad, Richmond, Calif.) with the pulse controller unit set at maximum
resistance. Cells (0.5 ml at a concentration of 107 cells per ml) were transfected
with 10 to 20 mg of transcript RNA and subsequently plated into two 60-mm
dishes. Specific infectivities derived from monolayers transfected with pWR3.26
transcripts were consistently above 107 PFU/mg of RNA, with ,10% of the cells
being killed by the transfection procedure alone. RNA transfection of a reporter
RNA transcript containing the 59NTR of HRV-14 fused to the b-galactosidase
coding sequence, followed by in situ staining for b-galactosidase activity (Pro-
mega), indicated that approximately 60 to 70% of cells were successfully trans-
fected (31).
Analysis of b-galactosidase and luciferase enzyme activity. Transfected cells
were processed for enzyme assays by the addition of 250 ml of lysis buffer
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(luciferase assay kit; Promega) per 60-mm dish. The protein content of the cell
lysates was determined by the Bradford method (protein assay; Bio-Rad), and
lysates were stored at 2708C until used in enzymatic analysis. For the b-galac-
tosidase assay, lysate containing 50 mg of protein was brought to 100 ml with lysis
buffer and then 100 ml of 23 assay buffer (200 mM sodium phosphate buffer [pH
7.3], 100 mM b-mercaptoethanol, 20 mM MgCl2, 16.0 mM chlorophenol red
b-D-galactopyranoside substrate [Boehringer-Mannheim Biochemicals]) was
added. Reaction mixtures were incubated at 378C for 30 min, and 300 ml of 1 M
sodium carbonate was added. Then 200 ml of each reaction mixture was trans-
ferred to a 96-well plate, and the A570 was read in a model EL309 microtiter plate
reader (BioTek Instruments Inc., Winooski, Vt.). For the luciferase assay, 5 ml of
lysate (or lysate diluted 1:10 with lysis buffer) was mixed with 100 ml of luciferase
substrate mixture (Promega). The samples were immediately monitored for light
output by using a BioOrbit model 1250 luminometer (LKB-Wallac, Turku, Fin-
land). Luciferase activities were normalized to the protein content of individual
cell lysates, while the b-galactosidase activities are reported as optical density
units at 570 nm per 50 mg of lysate protein.
RPA. The RNase protection assay (RPA) was carried out with reagents and
protocols supplied with the lysate RNase protection kit (United States Biochemi-
cals). Transfected-cell monolayers in 60-mm dishes were lysed by addition of 100
ml of a solution containing 4 M guanidine thiocyanate, 25 mM sodium citrate,
and 0.5% sarcosyl. Lysates were stored at 2708C until used for hybridization.
Riboprobes were prepared from a plasmid (pSPBP) containing HRV-14 genome
sequences from nt 5180 to 5446 inserted at the PvuII and XbaI sites in pSP64
(Promega). A bacteriophage SP6 promoter is situated 27 nt upstream of the
insert, resulting in production of a 290-nt runoff transcript following linearization
of the DNA with BstEII (nt 5183). A 263-nt stretch of this transcript represents
HRV-14 minus-strand RNA sequence which is protected from RNase digestion
following hybridization to plus strand-virus RNA. A control probe included in
hybridization reaction mixtures contained 100 nt of antisense human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene sequence. A plasmid contain-
ing this sequence under the control of the bacteriophage promoter T7 produces
a 139-nt unprotected runoff transcript (United States Biochemicals). For ribo-
probe synthesis, linearized template DNA (200 ng) was mixed with 2 ml of 103
transcription buffer (400 mM Tris-HCl [pH 7.6], 60 mM MgCl2, 50 mM dithio-
threitol, 20 mM spermidine-HCl), 1 ml each of ATP, GTP, and UTP at 10 mM,
1 ml of CTP at 0.5 mM, 5 ml of [a-32P]CTP (50 mM, 800 Ci/mmol; Dupont NEN,
Wilmington, Del.), 1 ml of RNasin (Promega), 2 ml (40 U) of RNA polymerase,
and diethylpyrocarbonate-treated H2O to 20 ml. The reaction mixtures were
incubated for 1 h at 378C for T7 polymerase (Promega or New England Biolabs)
or 408C for SP6 polymerase (Promega). Two units of RQ1-DNase (Promega)
was added, and the reaction mixtures were incubated at 378C for an additional 30
min. The reaction mixtures were brought to 100 ml with diethylpyrocarbonate-
treated H2O and purified over a Sephadex G-50 RNA spin column (Boehringer-
Mannheim Biochemicals). A 106-cpm portion of each probe was added to 45 ml
of lysate, and hybridization was carried out directly in lysate solutions at 378C for
18 h (overnight) as described by the manufacturer (United States Biochemicals).
The hybridization mixture was subsequently diluted 10-fold and digested with
RNase and proteinase, and protected RNA fragments were separated by elec-
trophoresis in 6% polyacrylamide–6 M urea gels and visualized by autoradiog-
raphy.
Metabolic labeling and immunoprecipitation of reporter proteins. After RNA
(or mock) transfection, cells were plated in complete medium and incubated at
348C for 1 h. The monolayers were washed five times with PBS and fed with 2 ml
of MEM containing 2.5 mg of actinomycin D per ml–5% dialyzed fetal calf
serum. Following incubation at 348C for 2 h, the monolayers were washed five
times with methionine-free MEM and refed with 1 ml of methionine-free MEM
containing actinomycin D and fetal calf serum, as above, and 100 mCi of [35S]me-
thionine (Dupont NEN). Following incubation for 5 h at 348C, the cultures were
washed five times with PBS and incubated at room temperature in lysis buffer (50
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40) for 15
min. The lysate was centrifuged for 2 min in a microcentrifuge, and the super-
natant was collected for immunoprecipitations. Immunoprecipitations with rab-
bit polyclonal anti-b-galactosidase or anti-luciferase antibodies were carried out
as previously described (7). Precipitated complexes were boiled in gel electro-
phoresis buffer for 3 min and analyzed by autoradiography following SDS-
polyacrylamide gel electrophoresis (PAGE).
RESULTS
Construction of candidate HRV-14 replicons. The HRV-14
genome is a polyadenylated 7,212-nt, positive-sense RNA mol-
ecule that contains a 59NTR of 628 nt, a large ORF encoding
a virus polyprotein of 2,179 amino acids, and a short 39NTR of
47 nt (8). As with other enteroviruses and rhinoviruses, the
ORF can be divided into three segments (P1, P2, and P3)
based on principal cleavages of the encoded polyprotein (for a
review, see reference 27), with the P1 segment encoding the
four capsid proteins. The HRV-14 59NTR contains elements
required for internal entry of ribosomes on uncapped viral
RNA (1) and for formation of RNA replication complexes
(44).
Candidate HRV-14 replicons were constructed from the
plasmid pWR3.26, which contains a full-length cDNA of rhi-
novirus type 14 under control of a T7 promoter (28). Since
several reports describe replication-competent poliovirus
(RNAs with large deletions including almost the entire P1
segment of that virus (3, 13, 24, 41), we initially constructed
two plasmids in which the pWR3.26 cDNA was altered to
include the bacterial b-galactosidase (pDP1bgal) or firefly lu-
ciferase (pDP1Luc) coding sequences in lieu of almost the
entire P1 segment of HRV-14 (Fig. 1A). These plasmids were
constructed by PCR amplification of the reporter gene se-
quences by using oligonucleotide primers with in-frame flank-
ing HRV-14 sequences and insertion of the amplified DNA
into appropriate restriction sites (BclI and AvrII) in pWR3.26
(see Materials and Methods). In each plasmid, the 59 end of
the reporter sequence was fused directly to the authentic ini-
tiator AUG of the HRV-14 polyprotein. In an effort to ensure
that recognition and processing at the VP1/2Apro cleavage was
not hampered by the presence of upstream foreign sequences,
the reporter sequences were inserted 7 codons upstream of this
Tyr-Gly dipeptide (Fig. 1). This configuration thus retained the
downstream amino acid residues that have been suggested to
be important for autocatalytic processing of the poliovirus
polyprotein by 2Apro (2, 21) and resulted in reporter-DVP1
fusion proteins containing the carboxyl-terminal 7 amino acids
of VP1 (Fig. 1B). The predicted mass of the b-galactosidase
fusion protein was approximately 118 kDa, while that for lu-
ciferase was 63 kDa. The HRV-14 RNA transcribed from
pDP1bgal was 462 bases (6.4%) longer than full-length rhino-
virus RNA, while DP1Luc RNA was 831 bases (11.5%) shorter.
Functional reporter proteins are expressed and processed
from DP1bgal and DP1Luc candidate replicon RNAs. To con-
firm that candidate replicon polyproteins were processed as
expected and that fusion of the reporter gene sequences had
not destabilized upstream RNA secondary structure required
for efficient cap-independent initiation of translation under
control of the HRV-14 internal ribosomal entry site (1), RNA
was transcribed in vitro from the plasmids pDP1bgal and
pDP1Luc by bacteriophage T7 RNA polymerase. This RNA
was transfected into H1-HeLa cells by an efficient electropo-
ration method which results in successful transfection of 60 to
70% of cells (see Materials and Methods). Transfected cells
were pulse-labeled with [35S]methionine from 3 to 8 h follow-
ing transfection. Labeled reporter proteins present in cell ly-
sates were immunoprecipitated with rabbit polyclonal antibod-
ies directed against b-galactosidase or luciferase and subjected
to SDS-PAGE (Fig. 2). Bands containing immunoreactive pro-
teins of the expected molecular mass were present in lysates of
cells transfected with either DP1Luc (Fig. 2, lane 3) or DP1bgal
(lane 4). These bands were not present in mock-transfected or
virus-infected cells (lanes 1 and 2, respectively). Thus, both
candidate replicons expressed a protein product in which 2Apro
accurately processed the reporter-VP1 fusion protein from the
remainder of the polyprotein.
Labeled, nonspecifically precipitated proteins were present
in lysates of mock-transfected cells and cells transfected with
the two candidate replicons (Fig. 2, lanes 1, 3, and 4). The
absence of these protein bands in lysates of virus-infected cells
(lane 2) most probably was due to 2Apro shutoff of host cell
protein synthesis. The absence of 2Apro shutoff in the trans-
fected cultures reflects the fact that only 60 to 70% of cells
were successfully transfected. Expression of the b-galactosi-
dase reporter protein from DP1bgal appeared to be at a lower
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level than luciferase expression from DP1Luc (compare lanes 3
and 4). This might be explained by different avidities of the
antibodies used in the immunoprecipitations. However, minor
immunoreactive protein products, which migrated more rap-
idly in SDS-PAGE than the intact b-galactosidase fusion pro-
tein did, were noted in cells transfected with DP1bgal upon
longer exposure of the gel shown in Fig. 2 (31). This suggested
the possibility that the somewhat lower expression levels ob-
served with DP1bgal reflect either aberrant translation or deg-
radation of the b-galactosidase reporter protein in vivo.
Lysates of cells transfected with the candidate replicons
were also examined for expression of reporter enzyme activity.
Figure 3 depicts the levels of b-galactosidase (Fig. 3A) or
luciferase (Fig. 3B) activities present in H1-HeLa cell lysates
prepared at various times following transfection of candidate
replicon RNAs. The temporal patterns of reporter protein
expression were similar for the two candidate replicons. While
measurable quantities of functional enzyme were present in
lysates prepared 3 to 12 h following transfection of either
RNA, enzyme activities did not increase over time as expected
from previous descriptions of successful poliovirus replicons
expressing heterologous reporter proteins (9, 36). The expres-
sion of b-galactosidase from DP1bgal appeared to peak at a
later time (9 h posttransfection [Fig. 3A]) than the luciferase
activity from DP1Luc (3 h [Fig. 3B]). This is probably a result
of the longer half-life of b-galactosidase than of luciferase (3)
and the potential for accumulation of this reporter product
(31). Furthermore, the functional b-galactosidase enzyme is a
tetramer, whose assembly may be delayed after translation,
while the luciferase enzyme functions as a monomer protein.
However, of greater importance, the activities of both reporter
proteins declined between 12 and 24 h, suggesting that less
RNA was available for translation and hence that there was a
failure of RNA replication.
To formally determine whether any of the enzyme activity
demonstrated in Fig. 3 could reflect replication of the input
RNAs, a frameshift mutation was created within the 3Dpol
coding region of both candidate replicons. This resulted in
FIG. 1. Construction of the DP1bgal and DP1Luc candidate replicons. (A) Full-length HRV-14 cDNA contained in pWR3.26 is under control of a T7 promoter
(28). The DP1bgal and DP1Luc replicons contain the b-galactosidase or luciferase sequences inserted in frame and replacing HRV-14 sequences between nt 628 and
3176. (B) The 59 and 39 in-frame fusions of the reporter sequences. At the 59 terminus, the reporter sequences are inserted at a BclI site which overlaps the authentic
AUG initiator for the HRV-14 polyprotein. At the 39 terminus, the reporter sequence is fused in frame to the carboxyl-terminal 7 amino acids of VP1, just upstream
of the 2Apro cleavage site. Constructions were done as described in Materials and Methods.
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pol2 mutant replicons, DP1bgal(pol2) and DP1Luc(pol2),
which encoded a truncated version of the viral 3Dpol RNA
polymerase lacking the conserved YGDD motif. There was no
reduction in the expressed enzyme activities following trans-
fection of these 3Dpol-mutated RNAs into H1-HeLa cells com-
pared with the reporter enzyme activities present following
transfection with intact candidate replicons (31). These results
indicated that the expression of reporter enzyme activity was
due to translation of the input RNA only and provided further
evidence that the DP1bgal and DP1Luc candidate replicons
were not capable of replication.
Analysis of DP1bgal and DP1Luc RNA replication by RPA.
To directly ascertain whether the candidate DP1bgal and
DP1Luc replicon RNAs were undergoing amplification follow-
ing transfection of H1-HeLa cells, the HRV-14 RNA content
of cell lysates was quantified by RPA at various time intervals
following transfection. For these measurements, equivalent
amounts of cell lysate were hybridized with an excess of radio-
labeled virus-specific RNA probe and then extensively digest-
ed with RNase, as described in Materials and Methods. A
second probe complementary to the cellular mRNA for human
GAPDH was included in each hybridization mixture to moni-
tor the cellular RNA content of the lysates. As shown in Fig. 4,
the amount of protected, virus-specific DP1bgal (Fig. 4A) or
DP1Luc (Fig. 4B) replicon RNA increased minimally or not at
all over the 24 h following transfection. While minimal in-
creases in the RNA signal were often observed between 0 and
6 h following transfection of the replicon RNAs, similar minor
increases were also observed with the 3Dpol mutant RNAs
(Fig. 4A), indicating that this was an artifact of the system and
was not indicative of RNA replication. The apparent failure of
these candidate replicons to sustain efficient RNA replication
was consistent with the results of reporter enzyme assays (Fig.
3), which failed to show an increase in enzyme activity indic-
ative of increasing abundance of a replicating, messenger-ac-
tive replicon RNA.
In contrast, a striking, sustained increase in the HRV-14
hybridization signal was always obtained following transfection
of infectious WR3.26 RNA (shown in both Fig. 4A and 4B). In
these experiments, cultures transfected with WR3.26 RNA
were maintained in medium containing a concentration of
neutralizing anti-HRV-14 antibody sufficient to prevent sec-
ond-cycle infection of any nontransfected cells. Therefore, the
RNA signal observed in these cultures should closely mimic
what would be expected with a successful HRV-14 replicon
RNA. The higher-molecular-weight bands that are HRV-14
specific and present only at late time points in cells transfected
with the replicating virus RNA are of unknown origin. Al-
FIG. 2. Processing of reporter proteins expressed from DP1bgal and DP1Luc.
2Apro processing of b-galactosidase–VP1 and luciferase-VP1 fusion proteins
resulted in immunoreactive proteins with predicted masses of 118 and 63 kDa
(arrows) in methionine-labeled cells transfected with DP1bgal RNA and DP1Luc
RNA. Similar proteins were absent from mock-transfected or virus-infected cell
extracts. Cell lysates were subjected to immunoprecipitation with anti-b-galac-
tosidase or anti-luciferase antibodies followed by electrophoresis on an SDS–
12% polyacrylamide gel and autoradiography.
FIG. 3. Enzyme activity produced following transfection of candidate repli-
cons. Cytoplasmic extracts were prepared at 0, 3, 6, 9, 12, and 24 h following
transfection with DP1bgal or DP1Luc RNAs. (A) Cells were transfected with
DP1bgal RNA (h) or mock transfected (■). Lysate containing 50 mg of protein
was analyzed for b-galactosidase activity as described in Materials and Methods.
(B) Cells were transfected with DP1Luc RNA (E) or mock transfected (F), and
5 ml of cell lysate was analyzed for luciferase activity. The luciferase activity was
normalized for the protein content of lysates. Results shown represent means
(6 range) of duplicate transfections.
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though surprising, these larger-than-probe-sized bands appear
to represent either the presence of stable duplexes which sur-
vive the denaturing gel conditions or the unexpected extension
of probe molecules acting as primers and annealing to positive-
strand RNAs present in the cell lysate (31).
We considered the possibility that the replicon plasmid
DNAs acquired a spurious mutation during subcloning and
passage in Escherichia coli and that this accounts for the lack of
RNA replication. To exclude this possibility, we reconstructed
a replicating virus genome by replacing the 59NTR–b-galacto-
sidase sequence (the small SalI-AvrII fragment) in pDP1bgal
with the analogous 59NTR-P1 sequence of HRV-14. Because
the HRV-14 59NTR/P1 sequence used in this reconstruction
was derived from a pol2 virus cDNA mutant, pWR3.26(pol2),
the replicating RNAs which were recovered from the recon-
structed clone must contain the P2-P3 segments of the
DP1bgal replicon. This result thus confirmed the integrity of
the P2-P3 segments in pDP1bgal. To ensure that there were no
adventitious mutations in the 59NTR, this region of pDP1bgal
was sequenced in its entirety.
Taken together, these results provide strong evidence that
subgenomic HRV-14 RNAs in which foreign RNA sequences
replace all but the 39 21 nt of the P1 segment of HRV-14 are
not capable of efficient replication. This lack of replication
capacity is not likely to be due to a unique feature of the
inserted RNA sequence, as it was observed with two distinctly
different foreign sequences inserted into the P1 region, one
longer and one shorter than the excised P1 sequence.
Deletion of capsid sequences compromises HRV-14 RNA
replication. The lack of replication of the candidate DP1bgal
and DP1Luc replicons, despite retention of an active internal
ribosomal entry site and processing of the expected reporter-
VP1 fusion protein at the VP1/2Apro junction, suggested that
sequences within the P1 region are necessary for efficient
HRV-14 RNA replication. To test this hypothesis, we con-
structed a series of five HRV-14 mutants which contained
various in-frame deletions within the P1 segment (Fig. 5). The
genomes of these mutants are similar to the genomes of pur-
posely constructed poliovirus defective interfering particles
that have been described previously (20, 24). We monitored
amplification of RNAs derived from these plasmids following
their transfection into H1-HeLa cells. As shown in Fig. 6,
increasing amounts of HRV-14 RNA were present in lysates
prepared at various intervals over the 24 h following transfec-
tion of three of the deletion mutants (CapD2, CapD3, and
CapD4). Replication of the viable mutant with the largest
deletion (CapD2 [Fig. 6]) appeared to proceed somewhat
more rapidly than replication of RNA from pWR3.26, the
full-length cDNA clone, while the increases in viral RNA seen
with the other two deletion mutants were very similar to the
intact RNA.
In contrast, the remaining two deletion mutant RNAs,
CapD1 and CapD5, were not amplified following transfection,
as evidenced by the lack of increasing amounts of protected
RNA fragments in the RPA (Fig. 6). These RNAs thus resem-
ble the nonviable DP1bgal and DP1Luc candidate replicons
(Fig. 4). As shown in Fig. 5, the two replication-incompetent
deletion mutants have a common deleted region, extending
from nt 2121 within the VP3 coding region to nt 2724 within
the VP1 coding region. It is unlikely that these deletion mu-
tants fail to replicate because of aberrant processing at the
VP1/2A site. The CapD1 and CapD5 transcripts encode dif-
ferent lengths of residual VP1 sequences, but in both cases the
retained VP1 segment is considerably longer than the 7 resi-
FIG. 4. RPA analysis of DP1bgal and DP1Luc RNA replication. Cell lysates were prepared at the indicated times following transfection with each candidate replicon
RNA or WR3.26 infectious RNA. Virus-specific RNA was detected in lysates by hybridization with an HRV-specific probe (HRV) followed by RNase treatment and
gel electrophoresis as described in Materials and Methods. An internal control probe (GAPDH) allowed monitoring of the cellular RNA content of each lysate. The
extreme right lane was loaded with aliquots of each probe representing 1:100 the amount used in individual hybridization reactions. Protected fragments that are specific
for virus (263 nt) and for GAPDH (100 nt) are indicated by arrows. (A) Transfection of DP1bgal, DP1bgal(pol2), and WR3.26 RNA transcripts; cell lysates were
prepared at 0, 3, 6, 9, 12, and 24 h following transfection. (B) Transfection of DP1Luc and WR3.26 RNAs prepared at 0, 6, 10, and 24 h following transfection. mock,
lysate of mock-transfected cells. All WR3.26 transfected cell cultures were maintained in medium containing neutralizing anti-HRV-14 antibody.
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dues present in DP1bgal and DP1Luc, which do undergo effi-
cient processing at this cleavage site (Fig. 2). Sequencing of
plasmid DNA confirmed that the deletions in these constructs
were in frame, as designed. Thus, these data strongly support
the conclusion that a 603-nt sequence located near the 39 end
of the P1 segment (nt 2121 to 2724) contains an element or
encodes a protein that is necessary for efficient replication of
HRV-14 RNA.
Addition of sequence from the 3* end of the P1 segment
restores replication competence to the DP1Luc replicon. Since
efficient RNA replication of P1 deletion mutants was obtained
only when sequences within the 39 region of the P1 segment
were retained (Fig. 6), we determined whether the presence of
this sequence would restore replication competence to the
DP1Luc candidate replicon. This was accomplished by insert-
ing into pDP1Luc the sequence spanning the region from nt
2117 (the NcoI site in VP3) to the 39 end of the P1 segment of
HRV-14 (see Materials and Methods for details of this con-
struction). A synthetic 3CDpro recognition and cleavage site
(Ala-X-X-Gln/Gly) was linked to the carboxyl-terminal lucif-
erase sequence (Fig. 7A). A -Gly-Gly-Gly- hinge was placed
between the luciferase sequence and this 3CDpro recognition
site to provide greater flexibility at the artificial cleavage site.
Processing by 3CDpro at this site should result in a luciferase
protein with only 7 additional carboxyl-terminal amino acid
residues and an expected mass of about 63 kDa. The design for
this synthetic 3CDpro cleavage site was based on 3CDpro rec-
ognition sites found in the HRV-14 polyprotein (8, 28) and on
the design of a similar functional synthetic poliovirus 3CDpro
cleavage site reported recently by others (4, 30). The synthetic
cleavage site includes a Gln-Gly dipeptide with an Ala residue
at the P4 position, which has been found to be important for
efficient 3CDpro processing in poliovirus (6, 16). The resulting
candidate replicon was designated DP1Luc/VP3.
RNA transcribed from pDP1Luc/VP3 was tested for its abil-
ity to produce properly processed luciferase protein by pulse-
labeling transfected H1-HeLa cells, and then immunoprecipi-
tating luciferase as described above. SDS-PAGE demonstrated
an immunoreactive protein of the expected mass in cells trans-
fected with DP1Luc/VP3 RNA (Fig. 7B, lane 4) but not in
mock-transfected or rhinovirus-infected cells (lanes 1 and 2,
respectively). Lack of processing at the synthetic 3CDpro cleav-
age site would have resulted in a fusion protein consisting of
the luciferase enzyme and 70 additional residues of VP3 (ap-
proximately 70 kDa). Immunoreactive proteins of this size
FIG. 5. Subgenomic HRV-14 constructs with P1 segment deletions. Shown is
a schematic diagram of the 5 HRV-14 in-frame P1 segment deletion mutants
created as described in Materials and Methods. The nucleotide positions flank-
ing the termini of each deletion are indicated. For the pCapD4 deletion, a linker
was inserted between the BclI and BglII sites to create a deletion beginning at the
AUG initiator codon and extending to the first nucleotide of the Thr-54 codon
at nt 788.
FIG. 6. Replication of P1-deleted mutant RNAs in H1-HeLa cells. Lysates were prepared at 0, 6, 10, or 24 h following transfection of cells with the indicated RNA
and processed for RPA as described in Materials and Methods. See the legend to Fig. 4 for details.
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were not apparent in DP1Luc/VP3-transfected cells (lane 4),
indicating efficient trans recognition and utilization of the syn-
thetic 3CDpro cleavage site within the DP1Luc/VP3 polypro-
tein. The abundance of the luciferase protein was significantly
greater in cells transfected with DP1Luc/VP3 RNA than in
cells transfected with DP1Luc (compare lanes 3 and 4). Since
equivalent amounts of replicon RNA were transfected in this
experiment, this provided preliminary evidence for replication
of the DP1Luc/VP3 RNA.
To confirm that DP1Luc/VP3 RNA was replicating, HRV-14
RNA was quantified by RPA of lysates derived from trans-
fected cells (Fig. 8). Control transfections carried out simulta-
neously included WR3.26 (full-length HRV-14) and DP1Luc
RNAs. Cell lysates were prepared as before, at various points
in time following transfection. Increasing quantities of virus-
specific RNA were evident in lysates of cells transfected with
DP1Luc/VP3 (Fig. 8). The RNA levels were similar to those
produced by intact HRV-14 transcripts in the same experi-
ment. As before, no significant increase in the RNA signal was
observed in cells transfected with DP1Luc RNA. Thus, the
addition of P1 sequences extending from nt 2117 to the P1/P2
junction resulted in restoration of replication competence to
the candidate DP1Luc replicon.
We compared the luciferase activity expressed in cells trans-
fected with DP1Luc/VP3 with that expressed following trans-
fection with DP1Luc (Fig. 9). Although the DP1Luc/VP3-trans-
fected cells contained approximately 5-fold less luciferase
activity than DP1Luc-transfected cells did (Fig. 9) 3 to 6 h after
transfection, this activity increased exponentially in DP1Luc/
VP3- but not in DP1Luc-transfected cells (Fig. 9) between 6
and 12 h. Thus, levels of luciferase at 12 and 24 h were over
100-fold greater than those present in DP1Luc-transfected
cells. This pattern of reporter protein expression is in agree-
ment with previous reports of successful poliovirus replicons
that express foreign proteins (3, 9, 36). The early delay in
luciferase expression from DP1Luc/VP3 compared with
DP1Luc (Fig. 9) may reflect sequestration of input RNA in
replication complexes, reducing the availability of the input
RNA for translation.
Capsid sequences provided in trans do not rescue nonrepli-
cating candidate HRV-14 replicons. To determine whether the
replication defect in DP1Luc could be complemented in trans,
cell monolayers which had been previously transfected with
replicon RNAs were infected with HRV-14 at high multiplicity
of infection. Under these conditions, the replicating virus ge-
nomes should provide an abundance of the capsid proteins
expressed by the P1 segment. If the capsid proteins (VP1 or
VP3 fragment expressed by DP1Luc/VP3) are important for
RNA replication and can function in trans, a nonreplicating
RNA such as DP1Luc might be rescued and undergo normal
RNA replication. For this experiment, cells were transfected
with DP1Luc or DP1Luc/VP3 RNAs and infected 6 h later with
HRV-14 at multiplicity of infection of 10 PFU per cell. Mono-
layers were assayed for luciferase enzyme activity 18 h later. As
shown in Table 1, the enzyme activity was not increased in
DP1Luc-transfected cells that were infected with HRV-14 but
was instead decreased (42% of control transfected cells).
These data thus suggest that the requirement for P1 sequences
in RNA replication cannot be provided in trans. The decrease
in luciferase activity observed with HRV-14 infection probably
reflects competition between the viral and candidate replicon
RNAs for cellular translation factors, as well as increased cell
death related to viral replication.
Compared with DP1Luc, the fractional decrease in luciferase
activity was substantially greater following virus infection of
cells which had been transfected previously with the DP1Luc/
FIG. 7. Organization of the DP1Luc/VP3 replicon. (A) HRV-14 sequences between nt 2118 and 3176 were reinserted in DP1Luc to create DP1Luc/VP3, as
illustrated. A synthetic 3CDpro recognition and cleavage site was placed at the carboxyl terminus of the luciferase sequence. (B) 3CDpro processing of luciferase from
the DP1Luc/VP3 polyprotein. An immunoreactive protein (arrow) of the predicted size was present in [35S]Met-labeled cells transfected with DP1Luc/VP3 RNA but
absent in mock-transfected or virus-infected cell extracts. Luciferase generated from cells transfected with DP1Luc RNA is shown for comparison. Cell lysates were
immunoprecipitated with rabbit antibody to luciferase and subjected to electrophoresis on an SDS–10% polyacrylamide gel. The minor immunoreactive band (at about
40 kDa) which migrated more rapidly in the DP1Luc/VP3 immunoprecipitation is likely a result of aberrant initiation or premature termination of translation.
1948 MCKNIGHT AND LEMON J. VIROL.
VP3 replicon (4% of uninfected control cells; Table 1). This
decrease could not be related to removal of RNA from the
pool of translating RNAs as a result of packaging of the rep-
licon, because a similar decrease was observed following co-
transfection with CapD2 RNA (Fig. 5), which does not encode
a complete set of capsid proteins (Table 1). This decrease in
luciferase expression is reflected by reduced DP1Luc/VP3
RNA replication, probably owing to competition from a more
efficiently replicating CapD2 or HRV-14 RNA (31). The ap-
parent difference in the replication efficiency of these RNAs
could be related to differences in their length (7,389 nt for
DP1Luc/VP3 versus 7,212 nt for HRV-14 and 5,846 nt for
CapD2). Importantly, DP1Luc/VP3 and CapD2 RNAs contain
similar HRV-14 P1 sequences (Fig. 5 and 7A).
DP1Luc/VP3 RNA is encapsidated during HRV-14 infection.
To determine whether DP1Luc/VP3 replicon RNA could be
packaged by capsid proteins provided in trans, transfected cell
monolayers were infected with HRV-14 as described above.
Virus harvests were prepared 18 h postinfection. Prior to in-
oculation onto fresh H1-HeLa cells, this first-passage virus was
treated with 1 mg of RNase A per ml to remove any free
replicon RNA. As shown in Table 2, cell lysates prepared from
monolayers inoculated with this virus harvest contained small
but readily detectable amounts of luciferase enzyme activity.
The expression of this luciferase activity could be completely
FIG. 8. RPA analysis of DP1Luc/VP3 RNA replication. Cell lysates were prepared at 0, 3, 6, 9, 12, and 24 h following transfection of the indicated RNA. See the
legend to Fig. 4 for details.
FIG. 9. Luciferase activity in cells transfected with DP1Luc/VP3 RNA. Cy-
toplasmic extracts were prepared at 0, 3, 6, 9, 12, and 24 h following transfection
with DP1Luc/VP3 RNA (F) or DP1Luc RNA (h) or mock transfection (■).
Results shown represent means (6 range) of duplicate transfections.
TABLE 1. Luciferase activity in H1-HeLa cells transfected with
candidate replicon RNAs and coinfected with HRV-14







DP1Luc None 164 (100)
HRV-14 69 (42)
DP1Luc/VP3 None 19,985 (100)
HRV-14 802 (4)
CapD2 781 (4)
a Helper genome supplied by infection with HRV-14 6 h following replicon
transfection or by simultaneous cotransfection of replicon and CapD2 RNAs.
b Luciferase values represent means of duplicate cultures assayed 24 h follow-
ing transfection (percent luciferase expression in the absence of helper genome
is given in parentheses).
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blocked by pretreatment of the virus harvest with neutralizing
antibody to HRV-14. In contrast, no luciferase activity was
present in cells inoculated with virus harvested from DP1Luc-
transfected cultures that were infected with HRV-14 or from
DP1Luc/VP3-transfected cultures that were not infected with
helper virus (Table 2). These results confirm that DP1Luc/VP3
replicon RNA is packaged by helper virus during infection.
However, no evidence for survival of the replicon RNA could
be obtained on subsequent passage of the virus-replicon mix-
ture (31), indicating that the packaged DP1Luc/VP3 genomes
were not stable in the helper virus population.
DISCUSSION
We have shown that an HRV replicon RNA, DP1Luc/VP3,
in which sequences encoding the firefly luciferase protein re-
placed the 59 1,488 nt of the P1 capsid-coding sequence of
HRV-14, replicated efficiently following its transfection into
H1-HeLa cells (Fig. 8). The luciferase activity expressed from
DP1Luc/VP3 RNA was dependent on replication of the RNA
genome (Fig. 9). In contrast, a similar candidate replicon,
DP1Luc, in which all but 21 nt of the HRV-14 P1 segment were
removed from the genome, failed to undergo efficient RNA
replication (Fig. 4B) and expressed only very low levels of
luciferase (Fig. 3B). While it is not possible to exclude a very
low level of replication of DP1Luc or the structurally related
DP1bgal candidate replicons, these RNAs did not undergo
amplification that was detectable in a sensitive RPA following
transfection of HeLa cells (Fig. 4). Intracellular RNA levels
remained similar to those present following transfection with
candidate replicon RNAs containing a lethal frameshift muta-
tion within the 3Dpol RNA polymerase coding region. These
results were consistent with the analysis of a series of sub-
genomic HRV-14 RNAs containing various in-frame deletions
within the P1 segment of the genome, which suggested that the
inclusion of sequence between nt 2121 and 2724 was essential
for replication of subgenomic HRV-14 RNAs (Fig. 6). How-
ever, the minimal sequence within this 603-nt segment which is
required for replication has yet to be determined.
Inefficient or aberrant processing of the HRV-14 polypro-
tein at the P1/P2 junction seems unlikely to account for the
lack of replication of DP1bgal, DP1Luc, or the capsid sequence
deletion mutants CapD1 and CapD5. Pulse-labeling experi-
ments demonstrated efficient processing of the 2Apro-directed
cleavage at the carboxyl terminus of the Luc-VP1 fusion pro-
tein expressed by DP1Luc (Fig. 2). Similarly, an immunoreac-
tive b-galactosidase protein of the expected size was present
in cells transfected with DP1bgal (Fig. 2). These observations
indicate the retention of autocatalytic processing of the poly-
protein of these replication-defective candidate replicons by
2Apro and are consistent with the retention of proteolytic ac-
tivity when poliovirus 2Apro was similarly fused to heterologous
sequences (2, 34, 41). Processing of the remaining P2/P3 por-
tion of the replicon polyprotein was not examined, because it is
expected to proceed normally after the primary 2Apro cleavage.
Although we did not examine the P1/P2 cleavage in cells trans-
fected with the capsid deletion mutants shown in Fig. 5, the
replication-defective mutants CapD1 and CapD5 encode poly-
proteins with carboxyl-terminal fragments of VP1 that are sub-
stantially longer than the 7 residues present in the DP1Luc and
DP1bgal polyproteins and are thus likely to be effectively pro-
cessed.
That P1 sequences appear to be required for efficient repli-
cation of HRV-14 RNA contrasts sharply with reports of po-
liovirus replicons which replicate well despite large deletions in
the P1 region (3, 13, 24, 41). However, it is interesting that
naturally occurring poliovirus defective interfering genomes
generally retain sequence at the 39 end of the P1 segment (20,
23, 26), although the downstream P1 sequences retained by
these genomes are significantly shorter than the P1 sequence
reinserted in DP1Luc/VP3 and encode only a truncated VP1
protein. The fact that candidate rhinovirus replicons which
lacked almost all of the P1 segment failed to replicate indicates
an important difference between these two otherwise quite
closely related viruses.
The required P1 sequence could function in several different
ways during the replication of HRV-14 RNA. The VP1 protein
is expressed as an intact protein by DP1Luc/VP3 and in each of
the replication-competent P1 deletion mutants. The analogous
poliovirus VP1 protein is closely associated with the mem-
brane-bound RNA replication complex in poliovirus-infected
cells (37). While this association has been assumed to reflect
the well-documented role of this protein in encapsidation of
RNA (25), an accessory function associated with RNA repli-
cation would be consistent with the tendency of picornavirus
proteins to fulfill multiple functions in viral replication. VP1
provided in trans by replicating HRV-14 helper virus did not
result in the rescue and replication of nonviable RNAs such as
DP1Luc (Table 1). While this does not rule out a cis-acting role
for VP1 in viral RNA replication, as is known to be the case for
several of the nonstructural proteins of poliovirus (43, 50), this
observation does argue against a trans-acting role for any of the
capsid proteins of HRV-14 in RNA replication. Further exper-
iments are required to determine whether the essential P1
sequence must be expressed as protein to support viral repli-
cation. The construction of dicistronic HRV-14 replicons may
be helpful in addressing this question (33).
It is also possible that this region of the P1 segment acts
directly as RNA in facilitating the replication of the HRV-14
genome. While such a P1 segment function is not suggested by
any current model of picornavirus RNA replication, the exis-
tence of a cis-acting replication signal located within this re-
gion of the viral genome would act to suppress the evolution of
defective interfering particles. Such an element would prevent
the amplification of RNA molecules sustaining large P1 dele-
tions that might, because of their shorter length, be otherwise
favored for replication. Interestingly, internally located, cis-
acting RNA replication elements are not without precedent
among plus-strand RNA viruses. Efficient synthesis of RNA-3
of brome mosaic virus, a positive-sense plant virus with a tri-
partite genome, requires the presence of internal sequences
which are located within an intercistronic region of this RNA
(18, 39, 42). These internal sequences may facilitate assembly
TABLE 2. Encapsidation of candidate replicon RNAs by





Luciferase activity (light units) on
passage to fresh H1-HeLa cellsa
Nonneutralized Postneutralization
DP1Luc None 0.01 NDb
HRV-14 0.03 ND
DP1Luc/VP3 None 0.07 ND
HRV-14 109 0.09
a Luciferase expression in H1-HeLa cells infected with RNase-digested lysates
of cells which had been transfected with replicon RNAs and infected with helper
virus as indicated. Lysates (first-passage virus harvests) were inoculated onto
fresh cells with or without prior incubation with anti-HRV-14 neutralizing anti-
body.
b ND, not determined.
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of an active brome mosaic virus RNA-dependent RNA poly-
merase complex required for negative-strand RNA-3 synthesis
in yeast cells (42), but they may not be absolutely required for
minus-strand initiation in plants, because a low level of RNA-3
replication proceeds in their absence (18). Recent work also
has revealed the presence of an internal cis-acting replication
signal located between 3.1 and 3.9 kb of the 59 end of a murine
coronavirus RNA genome (24a). Similar to the HRV artificial
defective interfering genomes described in this report, this
sequence was found to be required for efficient replication of
coronavirus defective interfering genomes.
Studies with the bacteriophage Qb replicase have demon-
strated a requirement for binding of the replicase complex to
two internal sites on the plus-strand RNA (5). Both the viral
replicase and a host factor bind to these internal sites, with
binding of the host factor possibly acting to bring the 39 end of
the genome into close proximity to the internal sites, thereby
allowing initiation of minus-strand RNA synthesis (5). It is not
difficult to imagine a similar event in the replication of picor-
navirus RNAs, although there are no prior data to suggest this.
The existence and nature of possible RNA secondary struc-
tures within the relevant region of the rhinovirus P1 coding
segment are not known, but alignment of available rhinovirus
sequences indicates the presence of several strong areas of
nucleotide sequence conservation (31). Multiple studies indi-
cate that the P1 segment of poliovirus is not required for
efficient RNA replication, but there are no data which would
exclude the possibility of such a cis-acting RNA replication
element within the P2/P3 segments of poliovirus. Interestingly,
Novak and Kirkegaard identified a region within the P2-P3
segments of the poliovirus genome which must undergo trans-
lation in cis for replication of the RNA to proceed (34a). It is
intriguing to speculate that the replication element we have
identified in HRV-14 may be analogous to this ‘‘cis-translation
required,’’ element of poliovirus but located within a different
region of the genome.
We found clear evidence for encapsidation of the DP1Luc/
VP3 RNAs following infection of previously transfected cells
with the HRV-14 helper virus (Table 2). However, luciferase
expression was very low when helper virus harvests were used
to infect fresh H1-HeLa cells, and in situ visualization of lu-
ciferase expression demonstrated only very small numbers of
infected cells (31). No luciferase activity was noted on further
passage of the helper-replicon mixture. At present, it is not
clear whether this reflects the inhibition of replicon replica-
tion by the helper viral genome or restrictions on packaging of
the longer-than-genome-length RNA. Additional experiments
were carried out in which the time of HRV-14 infection was
incrementally delayed up to 12 h after replicon transfection,
when substantial amounts of newly replicated RNA should
have been available for encapsidation. However, we observed
no significant increase in encapsidation of replicon RNA over
that shown in Table 2 (31). Although these results suggest that
the low levels of replicon encapsidation may be related to the
size or structure of RNA preferred by the HRV-14 packaging
mechanism, further studies are required to determine the mag-
nitude of any restriction to encapsidation.
The luciferase expressed by the DP1Luc/VP3 replicon pro-
vides a simple and sensitive marker for HRV-14 RNA repli-
cation. Since the pathogenesis of HRV infections is not well
understood, this or other replicons may be useful in studying
certain aspects of HRV pathogenesis, including the cell types
within the respiratory mucosa that are infected by HRV and
the routes by which the virus disseminates through the epithe-
lium of the upper airway during infection. Furthermore, the
unique tropism of HRV for cells of the respiratory mucosa
offers the possibility that HRV replicons expressing heterolo-
gous antigens or functional proteins will ultimately prove use-
ful as vaccine delivery systems or for targeted gene therapy.
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